程序性死亡 1 通路抑制在转移性肾细胞癌和前列腺癌中的应用。
Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.
机构信息
Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.
出版信息
Curr Oncol Rep. 2013 Apr;15(2):98-104. doi: 10.1007/s11912-012-0284-2.
Programmed death 1 (PD-1) is a T cell co-inhibitory receptor with two ligands, PD-L1 and PD-L2. In cancer, this pathway plays a major role in immune resistance in the tumor environment. Blockade of this pathway can enhance antitumor immune responses. This review discusses the preclinical rationale for PD-1 pathway inhibition in advanced renal cell carcinoma and prostate cancer, in addition to the clinical activity and toxicity of the anti-PD-L1 antibody BMS-936559, as well as anti-PD-1 antibodies MK-3475 and BMS-936558.
程序性死亡受体 1（PD-1）是一种 T 细胞共抑制受体，有两个配体，PD-L1 和 PD-L2。在癌症中，该通路在肿瘤微环境中发挥着主要的免疫抵抗作用。阻断该通路可以增强抗肿瘤免疫反应。本综述讨论了 PD-1 通路抑制剂在晚期肾细胞癌和前列腺癌中的临床前原理，以及抗 PD-L1 抗体 BMS-936559、抗 PD-1 抗体 MK-3475 和 BMS-936558 的临床活性和毒性。
Zotero 插件